Lidocaine Bp B. Braun Melsungen (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. By preventing sodium influx, it stops the generation and propagation of action potentials, thereby interrupting pain signal transmission and producing localized numbness in the treated area.

The appropriate dose is determined by the prescribing clinician based on the intended route (epidural, intradermal, intramuscular), the procedure, patient weight, age, and overall health status. Specific dosing instructions are provided in the product label and must be followed by the healthcare professional.

Safety data in pregnancy and lactation are limited. Use is generally reserved for situations where the expected benefit outweighs potential risk to the fetus or infant. Clinicians should evaluate each case individually and discuss possible effects with the patient before administration.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Lidocaine has a rapid onset (1–3 minutes) and intermediate duration (1–2 hours), whereas bupivacaine, a common alternative, has a slower onset but a longer duration (up to 6–8 hours). Lidocaine is often chosen for procedures requiring quick recovery, while bupivacaine is preferred for prolonged analgesia. Both share similar safety considerations, but bupivacaine carries a higher risk of cardiotoxicity at equivalent plasma concentrations.

Store the solution at controlled room temperature, typically below 25 °C, in its original sealed container. Protect it from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze. Inspect the vial for particulate matter or discoloration before use, and discard any product that appears compromised.

The product is supplied as a sterile solution for injection. It can be administered epidurally for analgesia, intradermally for skin testing, or intramuscularly for localized pain control. Administration must be performed by a qualified healthcare professional using aseptic technique and appropriate dosing guidelines for the selected route.

Serious adverse events include allergic reactions such as anaphylaxis, cardiac arrhythmias (especially ventricular tachycardia), central nervous system toxicity leading to seizures, methemoglobinemia, profound hypotension, and respiratory depression. Immediate medical attention is required if any of these symptoms develop during or after administration.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. It is also contraindicated in individuals with severe heart block, uncontrolled arrhythmias, or significant hepatic impairment that could impair metabolism. Clinicians should assess each patient’s medical history before prescribing.